Evaluation of the current treatment strategies for pancreatic neuroendocrine tumors.

Authors

null

Kenneth Lee Meredith

Florida State University College of Medicine/Sarasota Memorial Hospital, Sarasota, FL

Kenneth Lee Meredith , Taylor Maramara , Paige Blinn , Jamie Huston , Ravi Shridhar

Organizations

Florida State University College of Medicine/Sarasota Memorial Hospital, Sarasota, FL, Florida State University College of Medicine, Sarasota, FL, Sarasota Memorial Hospital, Sarasota, FL, University of Central Florida, Orlando, FL

Research Funding

No funding received
None

Background: The management of pancreatic neuroendocrine tumors (PNET) varies between observation (O), pancreatic resection (PR) and enucleation (E). Currently, size, grade and location are used to determine which treatment strategy may be employed. We sought to evaluate each strategy and further clarify the role for surgery. Methods: Utilizing the National Cancer Database we identified patients with pancreatic neuroendocrine tumors. Tumors were stratified based upon size <1cm, 1-2cm and >2 cm. Mann-Whitney U and Kruskal were used to compare continuous variables and Pearson’s Chi-square test was used to compare categorical variables. Unadjusted survival analyses were performed using the Kaplan-Meier method. Multivariate analysis (MVA) was performed to identify predictors of survival. All statistical tests were two-sided and p<0.05 was considered significant. Results: We identified 17,921 patients. (<1cm, 1214, 1-2cm, 4325, and >2cm, 12,382) with a median age of 61.5 (18-90). Males more often presented with tumors >2cm, 56% vs 44%, <0.001. Tumors >2cm were more likely to be poorly differentiated (PD), p<0.001, have node positive disease, p<0.001 and less likely to undergo R0 resection, p<0.001. Tumors <1cm and well differentiated (WD) the median and overall 5-year survival in the O group was not reached (NR) (77%) vs 142.6 months (87%) in the surgery groups, p<0.04; in the 1-2 cm WD group 95.7 months and 60% vs NR and 94%, p<0.001. Similarly in the PD tumors <1cm the median and overall survival was 32.9 months and 24% in the O vs NR and 81%, p<001; in the 1-2 cm group 14.8 months and 19% vs NR and 73%, p<0.001. There were no differences in survival in patients undergoing PR or E, p=0.09. MVA revealed age, grade, Charleson Deyo score, tumor size, tumor location, and surgery (PR or E) were all independent predictors of survival. Conclusions: While observation is currently an acceptable option for the management of small <1cm WD PNET, we found an improvement in survival in the patients undergoing surgery. Additionally, 1-2 cm PNET benefited from the surgical approach. Enucleation and pancreatic resection did not differ in overall survival. Surgery for PNET should be considered as the first line treatment of these patients.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer

Track

Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer

Sub Track

Patient-Reported Outcomes and Real-World Evidence

Citation

J Clin Oncol 38, 2020 (suppl 4; abstr 611)

Abstract #

611

Poster Bd #

F14

Abstract Disclosures

Similar Abstracts

First Author: Sri Harsha Tella

First Author: Mohamad Bassam Sonbol

First Author: Pranay Shah Ajay